Advances of nimotuzumab in the treatment of esophageal squamous cell carcinoma

VernacularTitle:尼妥珠单抗治疗食管鳞状细胞癌的应用进展
Author: Lichen DAI ¹ ; Lijun HU ; Jingping YU
Author Information

1. 南京医科大学附属常州第二人民医院放疗科，常州　213003
Keywords: Esophageal neoplasm; Nimotuzumab; Targeted therapy
From: Journal of International Oncology 2022;49(8):484-489
CountryChina
Language:Chinese
Abstract: Esophageal squamous cell carcinoma (ESCC) is the most predominant pathological type of esophageal cancer in China. In recent years, with the development of molecular targeted drugs, targeted therapy has become a hot research topic in the field of ESCC treatment. Nimotuzumab is the first humanized monoclonal antibody targeting epidermal growth factor receptor (EGFR) in China, which has been approved for the treatment of early or locally advanced nasopharyngeal carcinoma. Several phase Ⅱ-Ⅲ clinical trials have explored the use of nimotuzumab in the treatment of ESCC, confirming its significant efficacy and survival benefit in the treatment of advanced ESCC, as well as its favorable safety profile.